21:30 , Feb 19, 2019 |  BC Extra  |  Company News

HaiHe forms joint venture with CSPC, narrows focus to oncology

Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) formed a joint venture with CSPC Pharmaceutical Group Ltd. (HKSE:1093) to develop and commercialize five of HaiHe’s programs, mostly outside of oncology. Financial terms were not disclosed. HaiHe...
23:20 , Feb 13, 2019 |  BC Week In Review  |  Financial News

HaiHe raises $147M in series B to advance cancer candidates

Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) raised $146.6 million on Feb. 11 to advance its oncology focused pipeline in a series B round led by Huagai Capital. Also participating were Yingke PE, CSPC Pharmaceutical...
22:08 , Feb 11, 2019 |  BC Extra  |  Financial News

HaiHe raises $147M in series B to advance cancer candidates

Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) raised $146.6 million to advance its oncology focused pipeline in a series B round led by Huagai Capital. Also participating were Yingke PE, CSPC Pharmaceutical Group Ltd., Hillhouse...
20:03 , Feb 11, 2019 |  BC Extra  |  Company News

Agios' Schenkein joins GV

Less than two weeks after stepping down as CEO of Agios Pharmaceuticals Inc. (NASDAQ:AGIO), David Schenkein has joined GV as general partner. Schenkein, who will remain executive chairman of Agios, will co-lead the firm’s life...
19:30 , Dec 21, 2018 |  BC Week In Review  |  Company News

CSPC gains Chinese rights to I-Mab's GLP-1

TG103, a long-acting glucagon-like peptide-1 (GLP-1), is in Phase I testing in Germany. I-Mab Biopharma, Shanghai, China  CSPC Pharmaceutical Group Ltd. (HKSE:1093), Hong Kong, China  Business: Endocrine/Metabolic  I-Mab Biopharma (Shanghai, China) granted CSPC Pharmaceutical Group...
07:06 , Dec 18, 2018 |  BC Extra  |  Politics & Policy

China outlines adjuvant drug list

China’s National Health Commission announced plans to create a national adjuvant drug list and guidelines that could limit the sales of those drugs. A notice released last week called for the establishment of a system...
20:59 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Darzalex combo meets PFS endpoint in first-line MM

Genmab A/S (CSE:GEN; Pink:GMXAY) and Janssen Biotech Inc. said Darzalex daratumumab plus Revlimid lenalidomide and dexamethasone met the primary endpoint of improving progression-free survival (PFS) in the Phase III MAIA trial to treat newly diagnosed...
19:00 , Dec 7, 2018 |  BC Week In Review  |  Company News

Chinese biopharma stocks plummet after centralized tendering report

Chinese biopharma stocks tumbled Dec. 6 in the wake of media and analyst reports suggesting that pricing discounts on generic drugs under China's centralized procurement program were greater than expected. State-owned Shanghai Securities News reported...
01:15 , Dec 7, 2018 |  BC Extra  |  Company News

Chinese biopharma stocks plummet after centralized tendering report

Chinese biopharma stocks tumbled Thursday in the wake of media and analyst reports suggesting that pricing discounts on generic drugs under China's centralized procurement program were greater than expected. State-owned Shanghai Securities News reported significantly...
04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...